Indivior
As of the edition of 20 October 2026, Indivior runs 10 drugs, 4 of them marketed; it is on route A at 1 target and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Opiant Pharmaceuticals Inc: merged in 2024; successor Indivior Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 3 |
| Status not established | 2 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Risperidone | none listed | 2 |
| Naloxone | none listed | 10 |
| Nalmefene | none listed | 9 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 3 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Indivior needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Chemically induced: 7 trials led
- Mental health: 7 trials led
- Digestive system: 1 trials led